CANHelp Working Group Treatment Trials
Canadian North Helicobacter Pylori (CANHelp) Working Group Treatment Trials
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The CANHelp Working Group is a collaborative team that links University of Alberta researchers with Canadian northern community leaders and health officials in a collaborative effort to investigate H. pylori infection with the goal of finding solutions to community concerns about health risks. The research program uses a community-driven research approach in northern communities to characterize the burden of disease from H. pylori infection and exchange knowledge with community members and decision makers to identify ways to reduce health risks from this infection.
For the participating communities, the treatment trials aim to:
- Estimate the effectiveness of alternate H. pylori treatment regimens to identify optimal regimens for the local setting
- Identify factors external to the treatment regimen that influence short- and long-term treatment success
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2E1
- University of Alberta
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Over 15 years of age
- Identified as H. pylori infected with a positive urea breath test and/or biopsy-based evidence of H. pylori infection
Exclusion Criteria:
- Allergy to amoxicillin, metronidazole or clarithromycin
- Antibiotic therapy within 4 weeks prior to randomization
- Pregnant or breastfeeding
- Severe cardio-respiratory, pulmonary, endocrine, hepatic or renal disease
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Standard Triple, treatment naive
Standard Triple Therapy for H. pylori: Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg) One of two treatments randomly assigned to treatment naive participants in Aklavik |
Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)
Andre navne:
|
|
Aktiv komparator: Sequential, treatment naive
Sequential Therapy for H. pylori: Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg) One of two treatments randomly assigned to treatment naive participants in Aklavik, Old Crow, Tuktoyaktuk & Fort McPherson |
Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)
Andre navne:
|
|
Aktiv komparator: Quadruple, treatment naive
Quadruple Thearpy for H. pylori: Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily One of two treatments randomly assigned to treatment naive participants in Old Crow, Tuktoyaktuk & Fort McPherson |
Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily
Andre navne:
|
|
Aktiv komparator: Sequential, previous failure(s)
Sequential Therapy for H. pylori: Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg) One of two treatments randomly assigned to participants who previously failed one or more treatments in Aklavik, Old Crow, Tuktoyaktuk & Fort McPherson |
Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)
Andre navne:
|
|
Aktiv komparator: Quadruple, previous failure(s)
Quadruple Therapy for H. pylori: Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily One of two treatments randomly assigned to participants who previously failed treatment in Aklavik, Old Crow, Tuktoyaktuk & Fort McPherson |
Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily
Andre navne:
|
|
Aktiv komparator: Sequential, clarithromycin-resistant
Sequential Therapy for H. pylori: Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg) One of two treatments randomly assigned to participants with known clarithromycin resistance in Aklavik |
Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)
Andre navne:
|
|
Aktiv komparator: Quadruple, clarithromycin-resistant
Quadruple Therapy for H. pylori: Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily One of two treatments randomly assigned to participants with known clarithromycin resistance in Aklavik |
Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Post-treatment H. pylori status by urea breath test
Tidsramme: A minimum of 10 weeks after participant has completed treatment
|
Treatment effectiveness, defined as the probability (average risk) of elimination of H. pylori infection following treatment, measured as the proportion of trial participants with a negative post-treatment urea breath test at least 10 weeks following completion of treatment. Using an intention-to-treat analysis, the denominator for this proportion is the number of trial participants assigned treatment. Using a per-protocol analysis, the denominator for this proportion is the number of trial participants who completed treatment and were tested post-treatment. Participants are administered a urea breath test using 13C-labeled urea dissolved in a citric acid solution. We use the following test value classifications for determining the outcome: >=4.0 (Positive for H. pylori infection) Between 2.5 and 4.0 (Borderline; repeat test) Between 2.4 and -1.99 (Negative for H. pylori infection) Less than -2.0 (Uncertain test result, repeat test) |
A minimum of 10 weeks after participant has completed treatment
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Adherence to treatment regimen
Tidsramme: An expected average of 1 week after treatment is completed
|
Participants are asked to return blister packs with unused medication so skipped doses can be counted.
Participants are also interviewed to obtain details about their adherence to the regimen.
|
An expected average of 1 week after treatment is completed
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Frequency of adverse effects
Tidsramme: From the time treatment is started to an expected average of 1 week after treatment is completed
|
Participants are contacted by telephone during the completion of the treatment regimen and asked if they have experienced adverse effects.
Participants are also interviewed immediately after the completion of treatment and asked if they experienced adverse effects during the completion of treatment.
|
From the time treatment is started to an expected average of 1 week after treatment is completed
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Karen Goodman, PhD, University of Alberta
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- Pro00007868
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Helicobacter pylori infektion
-
Jianfeng XieRekrutteringCLABSI - Central Line Associated Bloodstream InfectionKina
-
Fondazione Policlinico Universitario Agostino Gemelli...Lo.Li.Pharma s.r.lIkke rekrutterer endnuHPV - Anogenital Human Papilloma Virus Infection | Infertilitet
-
Second Affiliated Hospital, School of Medicine,...AfsluttetHelicobacter pylori infektion | Helicobacter pylori udryddelsesantibiotikumKina
-
Catalysis SLRekrutteringH Pylori Infektion | H Pylori Gastritis | Gastritis forbundet med Helicobacter pylori | H Pylori udryddelse | MaveslimhindelæsionSerbien
-
Second Affiliated Hospital, School of Medicine,...Ikke rekrutterer endnuHELICOBACTER PYLORI INFEKTIONER | Redningsterapi for Helicobacter pylori
-
ImevaXAfsluttetHelicobacter Pylori-inficerede forsøgspersoner | Helicobacter Pylori naive emnerTyskland
-
Christopher C. Thompson, MD, MScErbe Elektromedizin GmbHRekrutteringHelicobacter pylori infektion | H. Pylori-infektion | Helicobacter pylori | Helicobacter Pylori mave-tarmkanalens infektion | H. Pylori Gastrointestinal sygdomForenede Stater
-
Daewoong Pharmaceutical Co. LTD.iNtherapeutics Co. LTDAfsluttetHelicobacter pylori infektion | Helicobacter Pylori-inficerede forsøgspersoner | Helicobacter pylori-inficerede patienterSydkorea
-
University of Santiago de CompostelaOsteology FoundationRekruttering
-
National Institute of Allergy and Infectious Diseases...RekrutteringHelicobacter pyloriForenede Stater
Kliniske forsøg med Standard Triple
-
Corporal Michael J. Crescenz VA Medical CenterAfsluttetIdiopatisk lungefibrose | KOL | Kongestiv hjertesvigt | Malignitet | Alvorlig eller meget alvorlig luftstrømsblokering og/eller modtagelse af eller berettiget til at modtage langvarig iltbehandling | Anden interstitiel lungesygdom uden helbredende terapi | NYHA Klasse IV eller NYHA Klasse III Plus... og andre forholdForenede Stater
-
University of PennsylvaniaRestaurant AssociatesAfsluttetFedme | Vægtøgning | Madpræferencer | Udvalg af madForenede Stater
-
University Hospital, BordeauxInstitut National de la Santé Et de la Recherche Médicale, France; Université... og andre samarbejdspartnereAfsluttetAlzheimers sygdomFrankrig
-
Yonsei UniversityRekrutteringTilbagevendende epitelial ovariecancerKorea, Republikken
-
Institute of Cardiology, Warsaw, PolandUkendt
-
Neuroscience Trials AustraliaNational Institute for Health Research, United Kingdom; Northern Ireland... og andre samarbejdspartnereAfsluttet
-
Riphah International UniversityRekrutteringKarpaltunnelsyndrom | HåndledsskaderPakistan
-
Second Affiliated Hospital, School of Medicine,...RekrutteringRotator Cuff Skader | Forreste korsbåndsskader | Skulderluksation eller subluksation | Afrivning af bagerste korsbånd | Skinnebensmeniskskader | Atletiske skader (C26.857.500.124)Kina
-
Micro Medical Solution, Inc.Aktiv, ikke rekrutterendePerifer arteriel sygdomForenede Stater